Comparison

ALNYLAM PHARMACEUTICALS, INC. (ALNY) vs NOVO NORDISK A S (NVO)

The same filed metrics for both companies, side by side.

What each names as a risk in its own annual report, how each is priced against its own history, and the tracked managers whose latest 13F reports a position in both.

Financials

ALNY

ALNYLAM PHARMACEUTICALS, INC.

Biotechnology

Revenue, FY25: $3.71B
Net income: $314M
Operating cash flow: $524M
Free cash flow: $465M
Net margin: 8.45%
Operating margin: 13.51%
Gross margin: 81.77%

NVO

NOVO NORDISK A S

Biotechnology

Revenue, FY25: $309B
Net income: $102B
Operating cash flow: $119B
Free cash flow: $58.96B
Net margin: 33.14%
Operating margin: 41.30%
Gross margin: 80.98%

Head-to-head

Filed growth, quality and valuation, read against each company’s own history rather than against the other side.

Metric	ALNY	NVO
Revenue growth, latest filed year	+65.19%	+6.43%
Piotroski F-score	5 of 8	5 of 9
P/E against its own history	-	-

What each says it is exposed to

From Item 1A of each company’s most recent 10-K.

ALNY

FDA approval
Reimbursement
Data privacy
Litigation
Tax
Product recalls

And 15 more.

NVO

No 10-K read yet.

Tracked managers holding both

Dodge & Cox Dodge & Cox 0.31% · 0.51%
Baillie Gifford Baillie Gifford & Co 0.67% · 0.00%
Joel Greenblatt Gotham Asset Management 0.03% · 0.00%

Updated Sep 17, 2026 · the newer of the two companies' filings